Company profile
Biogen Inc.
NASDAQ: BIIB · Healthcare · Drug Manufacturers - General
#43 of 1,422 Healthcare companies by revenue45th-percentile growth
EA Score
85AFH 83DQ 98GM 58SS 96
v0.1 · 65/100 weight · provisional
↑ disclosure history, market scale · ↓ 3-yr revenue growth, revenue growth (YoY)
Methodology →Revenue TTM
$9.9B
Rev growth YoY (TTM)
+0.4%
Net income (FY)
$1.3B
Employees
7,500
as of 2026-08-04
Market cap
$29.8B
as of 2026-08-04
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$9.9B$9.9B2025
Net income$1.3B$1.3B2025
Operating income$2.8B$2.8B2021
Total assets$29.4B$29.4B2025
Liabilities$11.2B$11.2B2025
Equity$18.3B$18.3B2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
MS Product Revenues42%
TYSABRI product17%
SPINRAZA16%
Fumarate15%
Interferon10%
By geography
Non-US60%
UNITED STATES40%
The read
What is Biogen Inc.’s revenue?
Biogen Inc. booked $9.9B in FY2025 revenue, growing 2.2% year over year — about the middle of the pack among Healthcare companies we track, at a 13.1% net margin.
Peers · Healthcare
Quest Diagnostics Incorporated88ABausch Health Companies Inc.82B+Intuitive Surgical, Inc.90AZoetis Inc.82B+Solventum Corporation65BZimmer Biomet Holdings, Inc.80B+Neighbors
Middlesex →Key facts
CEOChristopher A. Viehbacher
SectorHealthcare
IndustryDrug Manufacturers - General
HeadquartersCambridge, MA
ExchangeNASDAQ: BIIB
Employees7,500
IPO date1991-09-17
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.